Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s What Hedge Funds Think About Ascendis Pharma A/S (ASND)

How do we determine whether Ascendis Pharma A/S (NASDAQ:ASND) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that their consensus long positions have historically outperformed the market when we adjust for known risk factors.

Ascendis Pharma A/S (NASDAQ:ASND) shareholders have witnessed a decrease in hedge fund sentiment of late. ASND was in 33 hedge funds’ portfolios at the end of the second quarter of 2019. There were 35 hedge funds in our database with ASND holdings at the end of the previous quarter. Our calculations also showed that ASND isn’t among the 30 most popular stocks among hedge funds.

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey’s flagship best performing hedge funds strategy returned 25.8% year to date (through May 30th) and outperformed the market even though it draws its stock picks among small-cap stocks. This strategy also outperformed the market by 40 percentage points since its inception (see the details here). That’s why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.

Peter Kolchinsky

Unlike some fund managers who are betting on Dow reaching 40000 in a year, our long-short investment strategy doesn’t rely on bull markets to deliver double digit returns. We only rely on hedge fund buy/sell signals. Let’s analyze the fresh hedge fund action regarding Ascendis Pharma A/S (NASDAQ:ASND).

What have hedge funds been doing with Ascendis Pharma A/S (NASDAQ:ASND)?

At Q2’s end, a total of 33 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -6% from the first quarter of 2019. Below, you can check out the change in hedge fund sentiment towards ASND over the last 16 quarters. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were increasing their stakes substantially (or already accumulated large positions).

No of Hedge Funds with ASND Positions

More specifically, RA Capital Management was the largest shareholder of Ascendis Pharma A/S (NASDAQ:ASND), with a stake worth $475.9 million reported as of the end of March. Trailing RA Capital Management was OrbiMed Advisors, which amassed a stake valued at $442.9 million. Baker Bros. Advisors, Vivo Capital, and venBio Select Advisor were also very fond of the stock, giving the stock large weights in their portfolios.

Due to the fact that Ascendis Pharma A/S (NASDAQ:ASND) has faced bearish sentiment from hedge fund managers, we can see that there lies a certain “tier” of fund managers who were dropping their positions entirely by the end of the second quarter. Intriguingly, Oleg Nodelman’s EcoR1 Capital said goodbye to the largest position of the 750 funds followed by Insider Monkey, totaling about $42.5 million in stock. James E. Flynn’s fund, Deerfield Management, also said goodbye to its stock, about $17 million worth. These moves are intriguing to say the least, as total hedge fund interest was cut by 2 funds by the end of the second quarter.

Let’s now take a look at hedge fund activity in other stocks similar to Ascendis Pharma A/S (NASDAQ:ASND). These stocks are New Relic Inc (NYSE:NEWR), Acuity Brands, Inc. (NYSE:AYI), Grupo Televisa SAB (NYSE:TV), and Qurate Retail, Inc. (NASDAQ:QRTEA). This group of stocks’ market valuations are closest to ASND’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
NEWR 29 278012 2
AYI 23 928702 -6
TV 18 719110 2
QRTEA 33 639765 0
Average 25.75 641397 -0.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 25.75 hedge funds with bullish positions and the average amount invested in these stocks was $641 million. That figure was $2603 million in ASND’s case. Qurate Retail, Inc. (NASDAQ:QRTEA) is the most popular stock in this table. On the other hand Grupo Televisa SAB (NYSE:TV) is the least popular one with only 18 bullish hedge fund positions. Ascendis Pharma A/S (NASDAQ:ASND) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. Our calculations showed that top 20 most popular stocks among hedge funds returned 24.4% in 2019 through September 30th and outperformed the S&P 500 ETF (SPY) by 4 percentage points. Unfortunately ASND wasn’t nearly as popular as these 20 stocks and hedge funds that were betting on ASND were disappointed as the stock returned -16.4% during the third quarter and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks (view the video below) among hedge funds as many of these stocks already outperformed the market so far this year.
5 Most Popular Stocks Among Hedge Funds
Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.